๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mysore
Clinical trial register · India

Clinical Trials in Mysore

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 334 Mumbai 259 Hyderabad 238 Bangalore 194 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company5 Novartis Pharmaceuticals5 JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH2 AstraZeneca2 Tolmar Inc.2
Site location
New Delhi334 Mumbai259 Hyderabad238 Bangalore194 Pune189
All 273 locations
Target enrolment
to
29 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Eli Lilly and Company
Phase 3
2,001
Aligarh, Baroda, Guntur, Hubli, Jaipur, Mysore, Nagpur, Trivandrum
2026-09
Recruiting
HPTC Versus AFSM in Diabetic Foot Ulcers
NCT07781917Diabetic Foot Ulcer (DFU)
Adichunchanagiri Institute of Medical Sciences, B G Nagara
Not applicable
120
Mandya, Mysore
2026-08-28
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
NCT07613307Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
Eli Lilly and Company
Phase 3
130
Agra, Hyderabad, Kanpur, Kolkata, Mumbai, Mysore, Nashik, Nellore
2026-07-15
By invitation
Development of Anti-Diabetic Nutraceuticals From Legume Seed Coats
NCT07688694Postprandial Hyperglycemia, Type 2 Diabetes, Metabolic Syndromes
JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH
Not applicable
100
Mysore
2026-06-22
Recruiting
Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome
NCT07703371Obesity & Overweight, Metabolic Syndrome, Gut Dysbiosis, Insulin Resistance
JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH
Not applicable
50
Mysore
2026-06-01
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Ahmedabad, Bhubaneswar, Hyderabad, Kozhikode, Lucknow, Mysore, Pune, Varanasi
2026-03-23
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
Novartis Pharmaceuticals
Phase 2
210
Ahmedabad, Bangalore, Belagavi, Mysore, Nashik
2026-03-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Guntur, Guwahati, Hyderabad, Mandya, Mumbai, Mysore, Nagpur, Nashik
2026-02-06
Recruiting
Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria
NCT07680413Chronic Urticaria
Bharat Serums and Vaccines Limited
Observational
600
Ahmedabad, Vadodara, Faridabad, Gurgaon, Bangalore, Mysore, Aurangabad, Nanded
2025-12-31
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
Eli Lilly and Company
Phase 2
400
Aurangabad, Belgavi, Bhopal, Chhatrapati Sambhajinagar, Dehradun, Dharwad, Lucknow, Mysore
2025-11-24
Recruiting
Nuvastaticยฎ Phase III Trial for Fatigue in Triple-Negative Breast Cancer
NCT07669467Fatigue Related to Cancer Treatment, Breast Cancer
Natureceuticals Sdn Bhd
Phase 3
250
Visakhapatnam, Mysore, Jalgaon, Pune, Erode, Kanpur
2025-10-01
Recruiting
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastaticยฎ 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
NCT07669454Fatigue Related to Cancer Treatment, Colon Cancer
Natureceuticals Sdn Bhd
Phase 3
250
Visakhapatnam, Mysore, Jalgaon, Pune, Erode, Kanpur
2025-10-01
Recruiting
A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
NCT07157423Severe Postpartum Haemorrhage
Novo Nordisk A/S
Phase 4
64
Belagavi, Mysore, Kozhikode, Mumbai, New Delhi, Jaipur, Udaipur, Hyderabad
2025-08-26
Recruiting
ICU-related Out of Pocket Expenses (ICOPE)
NCT07439692Cost of ICU, Out of Pocket Expenses
Nat Intensive Care Surveillance - MORU
Observational
354
Mysore, Kochi, Pune, New Delhi, Chennai
2024-12-01
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Hyderabad, Surat, Vadodara, Mysore, Thiruvananthapuram, Mumbai, Nagpur, Pune
2024-09-04
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Bangalore, Mysore
2023-12-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
Akero Therapeutics, Inc
Phase 3
1,650
Surat, Vadodara, Mysore, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune
2023-12-01
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
470
Ahmedabad, Bangalore, Belagavi, Mysore, Nagpur, Nashik, New Delhi, Bikaner
2023-11-15
Active, closed
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Corcept Therapeutics
Phase 2
175
Guwahati, Ahmedabad, Rajkot, Surat, Vadodara, Rohtak, Mysore, Thiruvananthapuram
2023-10-25
Recruiting
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
NCT05865002Relapsed Malignant Solid Neoplasm
Aurigene Discovery Technologies Limited
Phase 1
50
Vijayawada, Visakhapatnam, Chandigarh, Ahmedabad, Surat, Rohtak, Bangalore, Mysore
2023-09-05
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
Eli Lilly and Company
Phase 3
3,127
Guntur, Bangalore, Mysore, Nagpur, Pune
2023-06-05
Recruiting
Yoga Based Cardiac Rehabilitation in Heart Failure Failure
NCT07817589Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Centre for Chronic Disease Control, India
Not applicable
3,500
Dharwad, Mysore, Shillong, New Delhi, Ludhiana, Jodhpur, Chennai, Rishikesh
2023-04-24
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guntur, Ahmedabad, Bangalore, Belagavi, Mangalore, Manipal, Mysore, Kochi
2023-03-09
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
Bristol-Myers Squibb
Phase 3
513
Ahmedabad, Hubli, Mysore, Nagpur, Vellore, Hyderabad, Secundarabad
2023-01-12
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
Tolmar Inc.
Phase 3
250
Surat, Bangalore, Bengaluru, Mysore, Nagpur, Nashik, Pune, Erode
2022-12-28
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Guntur, Hyderabad, Ahmedabad, Vadodara, Belagavi, Manipal, Mysore, Kochi
2021-11-23
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Bangalore, Belagavi, Jaipur, Mysore, Nashik
2021-10-28
Active, closed
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395Breast Cancer
Tolmar Inc.
Phase 3
250
Vijayawada, Visakhapatnam, Ahmedabad, Surat, Bengaluru, Mysore, Nagpur, Nashik
2021-07-01
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india/city/mysore

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.